Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Maarten Egeler"'
Autor:
Francesca Bagnasco, Stefanie-Yvonne Zimmermann, Rudolph Maarten Egeler, Vasanta Rao Nanduri, Bruna Cammarata, Jean Donadieu, Thomas Lehrnbecher, Riccardo Haupt
Publikováno v:
Data in Brief, Vol 45, Iss , Pp 108604- (2022)
This article presents the international dataset of cases in which the association of Langerhans cell Histiocytosis (LCH) with other malignancies (AM) was documented occurring at any age before, concurrently or after LCH. These data are mostly derived
Externí odkaz:
https://doaj.org/article/d1c37a6ac3b3454f9769fed06010172a
Autor:
Paul G. Kemps, Timo C. E. Zondag, Helga B. Arnardóttir, Nienke Solleveld-Westerink, Jelske Borst, Eline C. Steenwijk, Demi van Egmond, Joost F. Swennenhuis, Ellen Stelloo, Irene Trambusti, Robert M. Verdijk, Carel J. M. van Noesel, Arjen H. G. Cleven, Marijn A. Scheijde-Vermeulen, Marco J. Koudijs, Lenka Krsková, Cynthia Hawkins, R. Maarten Egeler, Jesper Brok, Tatiana von Bahr Greenwood, Karel Svojgr, Auke Beishuizen, Jan A. M. van Laar, Ulrike Pötschger, Caroline Hutter, Elena Sieni, Milen Minkov, Oussama Abla, Tom van Wezel, Cor van den Bos, Astrid G. S. van Halteren
Publikováno v:
Blood advances, 7(4), 664-679. American Society of Hematology
Langerhans cell histiocytosis (LCH) is a rare neoplastic disorder caused by somatic genetic alterations in hematopoietic precursor cells differentiating into CD1a+/CD207+ histiocytes. LCH clinical manifestation is highly heterogeneous. BRAF and MAP2K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af8313baedb40f4a65321041d0cf2628
https://doi.org/10.1182/bloodadvances.2022007947
https://doi.org/10.1182/bloodadvances.2022007947
Autor:
Paul G. Kemps, Timo C. Zondag, Eline C. Steenwijk, Quirine Andriessen, Jelske Borst, Sandra Vloemans, Dave L. Roelen, Lenard M. Voortman, Robert M. Verdijk, Carel J. M. van Noesel, Arjen H. G. Cleven, Cynthia Hawkins, Veronica Lang, Arnoud H. de Ru, George M. C. Janssen, Geert W. Haasnoot, Kees L. M. C. Franken, Ronald van Eijk, Nienke Solleveld-Westerink, Tom van Wezel, R. Maarten Egeler, Auke Beishuizen, Jan A. M. van Laar, Oussama Abla, Cor van den Bos, Peter A. van Veelen, Astrid G. S. van Halteren
Publikováno v:
Frontiers in Immunology, Vol 10 (2020)
Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed with various immune cells, including T cells. In 50–60% of LCH-patients,
Externí odkaz:
https://doaj.org/article/e72482c223694d18a86b7155b95eb24c
Autor:
Francesca Bagnasco, Stefanie Yvonne Zimmermann, Rudolph Maarten Egeler, Vasanta Rao Nanduri, Bruna Cammarata, Jean Donadieu, Thomas Lehrnbecher, Riccardo Haupt
Publikováno v:
European Journal of Cancer. 172:138-145
The frequency of Langerhans cell histiocytosis (LCH) and associated malignancies (AM) is greater than statistically expected. Here, we analyze LCH-AM co-occurrence in both children and adults.Between 1991 and 2015, data were collected by regular ques
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51a4111bba11793421edf03a769a58bc
https://doi.org/10.1016/j.ejca.2022.03.036
https://doi.org/10.1016/j.ejca.2022.03.036
Autor:
Juan Carlos Fierro-Pineda, Hua-Ling Tsai, Amanda L Blackford, Andrew Cluster, Emi H Caywood, Jignesh Dalal, Jeffrey H Davis, R. Maarten Egeler, Jeffrey Huo, Michelle Hudspeth, Amy K. Keating, Susan S Kelly, Joerg Krueger, Dean A Lee, Leslie Elaine Lehmann, Lisa Madden, Benjamin R Oshrine, Michael A Pulsipher, Terry J Fry, Heather J Symons
Publikováno v:
Blood Advances.
Promising results have been reported for adult patients with high-risk hematologic malignancies undergoing haploidentical bone marrow transplant (haploBMT) with post-transplantation cyclophosphamide (PTCy). We report results from the first multicente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ea4e6f0d0b7c5850d1fe70db1cd3feb
https://doi.org/10.1182/bloodadvances.2023010281
https://doi.org/10.1182/bloodadvances.2023010281
Autor:
Deepak Chellapandian, Polyzois Makras, Gregory Kaltsas, Cor van den Bos, Lamia Naccache, Raajit Rampal, Anne-Sophie Carret, Sheila Weitzman, R. Maarten Egeler, Oussama Abla
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 8, Iss 0, Pp e2016033-e2016033 (2016)
Background: Bone is the most common organ of involvement in patients with Langerhans cell histiocytosis (LCH), which is often painful and associated with significant morbidity from pathological fractures. Current first-line treatments include chemoth
Externí odkaz:
https://doaj.org/article/5735325a8e08420c8d23087bb62ca3e8
Autor:
Friso G.J. Calkoen, Carly Vervat, Else Eising, Lisanne S. Vijfhuizen, Peter-Bram A.C. ‘t Hoen, Marry M. van den Heuvel-Eibrink, R. Maarten Egeler, Maarten J.D. van Tol, Lynne M. Ball
Publikováno v:
Haematologica, Vol 100, Iss 11 (2015)
An aberrant interaction between hematopoietic stem cells and mesenchymal stromal cells has been linked to disease and shown to contribute to the pathophysiology of hematologic malignancies in murine models. Juvenile myelomonocytic leukemia is an aggr
Externí odkaz:
https://doaj.org/article/16effb71d68443fc904da1a113b797b8
Autor:
Hisaki Fujii, Zhi-Juan Luo, Hye Jin Kim, Susan Newbigging, Adam Gassas, Armand Keating, R Maarten Egeler
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133216 (2015)
Chronic graft-versus-host disease (cGvHD) is the major source of late phase morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Humanized acute GvHD (aGvHD) in vivo models using NOD-SCID il2rγ-/- (NSG) mice are well des
Externí odkaz:
https://doaj.org/article/71cb522c128d4e9f809bc12a1934cf51
Autor:
Milen Minkov, Peter Beverley, Christopher K. Glass, Florent Ginhoux, Carl E. Allen, Eli L. Diamond, Astrid G. S. van Halteren, R. Maarten Egeler, Matthew Collin, Barrett J. Rollins
Publikováno v:
Nature Immunology, 21(1), 1-7. NATURE PUBLISHING GROUP
Progress in understanding the rare disease Langerhans cell histiocytosis has stimulated immersive meetings occurring annually over a 30-year period that bring together clinicians, scientists and patients in a unique collaboration.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3476f3427c600543d0f0ec0f18bf2f6e
https://hdl.handle.net/1887/3181396
https://hdl.handle.net/1887/3181396
Autor:
Paul G, Kemps, Timo C, Zondag, Eline C, Steenwijk, Quirine, Andriessen, Jelske, Borst, Sandra, Vloemans, Dave L, Roelen, Lenard M, Voortman, Robert M, Verdijk, Carel J M, van Noesel, Arjen H G, Cleven, Cynthia, Hawkins, Veronica, Lang, Arnoud H, de Ru, George M C, Janssen, Geert W, Haasnoot, Kees L M C, Franken, Ronald, van Eijk, Nienke, Solleveld-Westerink, Tom, van Wezel, R Maarten, Egeler, Auke, Beishuizen, Jan A M, van Laar, Oussama, Abla, Cor, van den Bos, Peter A, van Veelen, Astrid G S, van Halteren
Publikováno v:
Frontiers in Immunology
Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed with various immune cells, including T cells. In 50–60% of LCH-patients,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8d75faf6a4dde412a3c6b61f078ca317
https://pubmed.ncbi.nlm.nih.gov/31998317
https://pubmed.ncbi.nlm.nih.gov/31998317